Patents by Inventor Thomas V. Magee
Thomas V. Magee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7462600Abstract: Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.Type: GrantFiled: December 21, 2005Date of Patent: December 9, 2008Assignee: Pfizer IncInventors: Louis S. Chupak, Mark E. Flanagan, Takushi Kaneko, Thomas V. Magee, Mark C. Noe, Usa Reilly
-
Publication number: 20080293646Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and X are as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of Formula (I).Type: ApplicationFiled: March 12, 2008Publication date: November 27, 2008Inventors: Thomas V. Magee, Usa Reilly, Mark Carl Noe, Mark E. Flanagan, Zhengong Bryan Li, Richard Allen Buzon, Daniel William Widlicka
-
Patent number: 7250518Abstract: Compounds of the formula: useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils.Type: GrantFiled: February 17, 2004Date of Patent: July 31, 2007Assignee: Pfizer Inc.Inventors: Thomas V. Magee, Anthony Marfat, Robert J. Chambers
-
Patent number: 7183293Abstract: This application is directed to compounds of the formula wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W1 and W2 are independently —O— or —S(?O)t—, where t is 0, 1, or 2; Y is ?C(R1a)—, where R1a is a member selected from the group consisting of H; F; Cl; CN; NO2; —(C1–C4)alkyl; —(C2–C4)alkynyl; fluorinated-(C1–C3)alkyl; fluorinated-(C1–C3)alkoxy; —OR16; and —C(?O)NR22aR22b; R22a and R22b are defined as set forth in the specification; —RA and RB are each a member independently selected from the group consisting of H; F; CF3; —(C1–C4)alkyl; —(C3–C7)cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R10, which is defined as set forth in the specification; R16 and R17 are defined as set forth in the specification; —RC and RD have the same meaning as defined above for RA and RB except that one of them must be —H, and they are selected independently of each other and of RA and RB; R1 and R2 are each a membType: GrantFiled: August 13, 2004Date of Patent: February 27, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Anthony Marfat, Robert J. Chambers, Thomas V. Magee
-
Patent number: 7060717Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.Type: GrantFiled: June 9, 2004Date of Patent: June 13, 2006Assignee: Pfizer IncInventors: Simon Bailey, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
-
Patent number: 6953810Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, or 2; n is 1 or 2; W1 is —O—; or —S(?O)t—, where t is 0, 1, or 2; or —N(R3)—; W2 is —O—CRARB— or is absent; Y is ?C(R1a)— or —[N?(O)k]— where k is 0 or 1; RA and RB are —H; —F; —CF3; —(C1-C4)alkyl; —(C3-C7) cycloalkyl; phenyl; or benzyl substituted with 0 to 3 substituents R10; or RA and RB are taken together, but only in the case where m is 1, to form a spiro moiety; RC and RD have the same meaning as RA and RB except that one of them must be —H, R1 and R2 are —H; —F; —Cl; —CN; —NO2; —(C1-C4)alkyl; —(C2-C4)alkynyl; fluorinated-(C1-C3)alkyl; —OR16; and —C(?O)NR22aR22b; R3 is —H; —(C1-C3)alkyl; phenyl; benzyl; or —OR16; R4, R5 and in addition to other meanings may be taken together to form, e.g.Type: GrantFiled: July 2, 2003Date of Patent: October 11, 2005Assignee: Pfizer IncInventors: Robert J. Chambers, Anthony Marfat, Thomas V. Magee
-
Patent number: 6949573Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.Type: GrantFiled: February 6, 2003Date of Patent: September 27, 2005Assignee: Pfizer IncInventors: Simon Bailey, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
-
Patent number: 6828333Abstract: This application is directed to compounds of the formula wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W1 and W2 are independently —O— or —S(═O)t—, where t is 0, 1, or 2; Y is ═C(R1a)—, where R1a is a member selected from the group consisting of H; F; Cl; CN; NO2; —(C1-C4) alkyl; —(C2-C4) alkynyl; fluorinated-(C1-C3) alkyl; fluorinated-(C1-C3) alkoxy; —OR16; and —C(═O)NR22aR22b; R22a and R22b are defined as set forth in the specification; —RA and RB are each a member independently selected from the group consisting of H; F; CF3; —(C1-C4) alkyl; —(C3-C7) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R10, which is defined as set forth in the specification; R16 and R17 are defined as set forth in the specification; —RC and RD have the same meaning as defined above for RA and RB except that oneType: GrantFiled: January 31, 2002Date of Patent: December 7, 2004Assignee: Pfizer Inc.Inventors: Anthony Marfat, Robert J. Chambers, Thomas V. Magee
-
Publication number: 20040224975Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.Type: ApplicationFiled: June 9, 2004Publication date: November 11, 2004Applicant: Pfizer Inc.Inventors: Simon Balley, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
-
Publication number: 20040171798Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1Type: ApplicationFiled: February 17, 2004Publication date: September 2, 2004Applicant: Pfizer IncInventors: Thomas V. Magee, Anthony Marfat, Robert J. Chambers
-
Patent number: 6756392Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions as well as for wounds healing.Type: GrantFiled: February 6, 2003Date of Patent: June 29, 2004Assignee: Pfizer IncInventor: Thomas V. Magee
-
Publication number: 20040048903Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1Type: ApplicationFiled: July 2, 2003Publication date: March 11, 2004Applicant: Pfizer Inc.Inventors: Robert J. Chambers, Anthony Marfat, Thomas V. Magee
-
Publication number: 20030220361Abstract: The invention relates to a combination of a nicotinamide derivative and tiotropium or a derivative thereof, compositions containing it and the uses of, such a combination. The combination according to the present invention is useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: ApplicationFiled: February 6, 2003Publication date: November 27, 2003Inventors: Simon Bailey, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
-
Publication number: 20030220366Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.Type: ApplicationFiled: February 6, 2003Publication date: November 27, 2003Inventors: Simon Bailey, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
-
Patent number: 6649633Abstract: This application is directed to compounds useful as inhibitors at PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis and chronic obstructuive pulmonary disease, of the formula: where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, or 2; n is 1 or 2; W1 is —O—; or —S(═O)t—, where t is 0, 1, or 2; Y is —C(R1a); Q1 is phenyl or substituted phenyl; Q2 is biphenyl or substituted biphenyl; and the remaining variables are defined as set forth in the specification. This application is also directed to pharmaceutical compositions comprising those compounds and to methods of treating diseases regulated by the activation and degranulation of eosinophils, in particular asthma, chronic bronchitis and chronic obstructive pulmonary disease.Type: GrantFiled: January 31, 2002Date of Patent: November 18, 2003Assignee: Pfizer IncInventors: Robert J. Chambers, Anthony Marfat, Thomas V. Magee
-
Publication number: 20030195233Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions as well as for wounds healing.Type: ApplicationFiled: February 6, 2003Publication date: October 16, 2003Inventor: Thomas V. Magee
-
Publication number: 20030191158Abstract: The invention relates to a combination of a nicotinamide derivative and tiotropium or a derivative thereof, compositions containing it and the uses of, such a combination. The combination according to the present invention is useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: ApplicationFiled: February 6, 2003Publication date: October 9, 2003Inventor: Thomas V. Magee
-
Publication number: 20030027845Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1Type: ApplicationFiled: January 31, 2002Publication date: February 6, 2003Applicant: Pfizer Inc.Inventors: Anthony Marfat, Robert J. Chambers, Thomas V. Magee
-
Publication number: 20020193612Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1Type: ApplicationFiled: January 31, 2002Publication date: December 19, 2002Applicant: Pfizer Inc.Inventors: Robert J. Chambers, Anthony Marfat, Thomas V. Magee
-
Patent number: 5527924Abstract: The present invention provides two basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogs to taxol. Both the intermediates and analogs to taxol may prove to be valuable anticancer agents.Type: GrantFiled: December 5, 1994Date of Patent: June 18, 1996Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, William G. Bornmann, Yves Queneau, Thomas V. Magee, Walter J. Krol